Photo via New York Post

New Chinese weight-loss drug produces bigger results than Wegovy in under a year

Read the original at New York Post ↗
Cite

Beard, M. (2026, November 16). New Chinese weight-loss drug produces bigger results than Wegovy in under a year. New York Post. https://nypost.com/2026/11/16/health/new-chinese-weight-loss-drug-produces-bigger-results-than-wegovy/

Dated from the outlet's own feed. Check the original for its byline.

New York Post · collected 2026-11-16 · by McKenzie Beard

Quick Summary

A new Chinese weight-loss drug, ribupatide, has shown promising results in clinical trials, helping participants lose up to 17.7% of their body weight in under a year. Developed by Chinese pharmaceutical company Hengrui and tested in a 48-week trial involving 567 overweight or obese adults, ribupatide outperformed a placebo, with the highest dose group losing an average of 17.7% of their body weight. This performance is comparable to and possibly superior to that of Wegovy, another popular weight-loss drug. In addition to significant weight loss, ribupatide also improved blood sugar, blood pressure, and cholesterol levels, and reduced waist circumference more effectively than the placebo.
Written by AI on 2026-11-17, from this article's own text only (the story summary below draws on all the coverage).
See how they differ ↓

Compared with similar articles

This article reads unscored and hedges 10% of its claims. Each row says how that neighbour differs.

Story

Chinese Weight Loss Jab Outperforms Competitors
Other · 2 article(s) covering the same event. See how they differ ↑
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
29
sentences that state something as happening or true
Uncertain
10%
3 of 29 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
66/100
New York Post's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
2
Other
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-17 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

New York Post · 21075 article(s) · 41 correction(s) detected
Running correction rate · 41 correction(s)

Who wrote this

McKenzie Beard
22 article(s) here · 1 carrying a prediction
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.
Warning signs may include painless vision loss in one eye — which patients may first notice upon waking — as well as blurred vision, missing patches of sight, distorted colors and hazy spots affecting central vision.
A Virginia woman in the throes of a life-threatening allergic reaction was told to cough up hundreds of dollars before a nurse would administer an EpiPen.
“He has been held in the warm embrace of family and friends, surrounded by live music, prayer, tears, laughter, and the kind of profound emotion that only he could inspire after a lifetime of devotion to us all,” read a statement posted Thursday to Stewart’s Instagram page.
Today, they’re attracting an increasingly mainstream crowd, with many betting that these once-taboo substances could be the next big thing in mental health.
Zyn may have taken nicotine pouches mainstream, but we’ve come a long way since the brand popularized the “lip pillow.”
But that scan may reveal more than just how the girls are doing.
Holding your breath may be more than just a good party trick.
The findings, from Canada, could be a warning sign for the US, where the activity has taken off in recent years.
“I was searching for a magical reset button where I didn’t have to take time off and it would take care of all of my misbehavior and all of my poor choices would be erased and I would feel anew again,” Stratton, who lives in Palm City, Florida, said.
Also by McKenzie Beard
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 22 articles by McKenzie Beard →

Topics

Chinese Fudan University Hengrui Kailera Therapeutics Shanghai

Subjects

Chinese NORP · 2× Americans NORP · 1× China GPE · 1× Eli Lilly’s ORG · 1× Fudan University ORG · 1× Hengrui ORG · 1× Kailera Therapeutics ORG · 1× Mounjaro PERSON · 1× Shanghai GPE · 1× Wegovy PERSON · 1×

Narrative

Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week.
framing: assertive · carried by 1 article(s) · first seen 2026-11-17
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year.

Claims (29 extracted, 3 hedged)

The race for the tiniest waist just got even more competitive. asserted
race → get → waist
New clinical trial results suggest a Chinese-made weight-loss drug could help people shed nearly 18% of their body weight in under a year. uncertain
people → suggest → year
The findings suggest the newcomer could one day outperform some of the biggest names in the booming GLP-1 market, including Wegovy and Mounjaro. uncertain
newcomer → suggest → Wegovy
In the 48-week trial, researchers from Fudan University in Shanghai recruited 567 adults who were overweight or obese and divided them into four groups. asserted
who → recruit → groups
Three groups received weekly injections of ribupatide at doses of 2 milligrams, 4 milligrams or 6 milligrams, while the fourth received a placebo. asserted
fourth → receive → placebo
Behind the experimental drug is Chinese pharmaceutical giant Hengrui, which partnered with US biotech firm Kailera Therapeutics to bring ribupatide to markets outside China. asserted
which → partner → China
Ribupatide works by mimicking two hormones naturally produced in the gut that help regulate appetite, digestion and blood sugar. asserted
that → work → appetite
It’s a similar approach to that used by Eli Lilly’s blockbuster drugs Mounjaro and Zepbound. asserted
It → ’ → drugs
But ribupatide has been designed to bind more tightly to its targets and stay active in the body longer, potentially extending its effects throughout the week. asserted
ribupatide → design → week
Everyone in the study — including those given placebo shots — also followed a lifestyle program that included dietary counseling and recommendations to get at least 150 minutes of moderate exercise each week. asserted
that → include → exercise
After 48 weeks, those taking the lowest dose of ribupatide had lost an average of 10.7% of their starting body weight. asserted
those → take → weight
Those on the 4-milligram dose shed 16.4%, while participants taking the highest dose lost a whopping 17.7%. asserted
participants → shed → %
The placebo group lost just 1.4%. asserted
group → lose → %
The numbers are in the same ballpark as — and potentially higher than — those seen with Wegovy. asserted
numbers → see → Wegovy
In a separate clinical trial, people taking a 2.4 mg dose of the popular GLP-1 shot lost an average of 14.9% of their body weight over a longer period of 68 weeks. asserted
people → take → weeks
Weight loss hadn’t started to level off among participants taking the two highest doses by the end of the 11-month study, suggesting they could have lost even more with longer treatment. uncertain
they → start → treatment
And the benefits extended beyond the scale. asserted
benefits → extend → scale
Although none of the participants had diabetes, researchers found that those taking ribupatide had reductions in blood sugar. asserted
those → have → sugar
They also saw improvements in blood pressure and cholesterol. asserted
They → see → pressure
Their waistlines shrank, too — an important measurement because abdominal fat is linked to an increased risk of heart disease and other health problems. asserted
fat → shrink → disease
The participants taking ribupatide saw their waist measurements drop by between 9 and 14 centimeters, compared with just 2.5 centimeters among those on the placebo. asserted
measurements → take → placebo
Like other GLP-1s, ribupatide most commonly caused digestive problems, including nausea, vomiting and diarrhea. asserted
ribupatide → cause → nausea
The researchers said the symptoms were generally mild to moderate and occurred most often as participants increased their doses. asserted
participants → say → doses
Study authors said their results are promising and come amid a need for more pharmacological treatment options as obesity continues to plague millions of people. asserted
obesity → say → people
The problem is particularly acute in the US, where roughly four in 10 adults have obesity and an even larger share are overweight. asserted
share → have → obesity
Among children and teenagers ages 2 to 19, just over 21% have obesity. asserted
% → have → obesity
It’s no wonder Americans’ appetite for weight-loss injections shows little sign of slowing. asserted
appetite → ’ → slowing
A September Gallup survey found that 11% of US adults were currently taking a GLP-1 medication for weight loss, up from just 3% in 2024. asserted
% → find → 2024
Overall, 15% said they had taken one of the blockbuster drugs at some point in their lives — a jump of nine percentage points in just two years. asserted
they → say → years
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support